NEW YORK (GenomeWeb News) – CombiMatrix today raised the expected net proceeds from an intended public offering of its securities.

In a document filed with the US Securities and Exchange Commission, the company said that net proceeds from its proposed offering of 10,000 shares of Series D preferred stock is now estimated at up to $12.2 million, an increase from a previous estimate of up to $10.4 million.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Lawmakers have asked four direct-to-consumer genetic testing companies to explain their privacy policies and security measures, according to Stat News.

The Trump Administration has proposed a plan to reorganize the federal government, the Washington Post reports.

In Science this week: genetic overlap among many psychiatric disorders, and more.

The Economist writes that an increasing number of scientific journals don't do peer review.